{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:44:08Z","timestamp":1792806248620,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Die nicht-interventionelle Beobachtungsstudie analysierte mit einem retro- und prospektiven Design die Behandlungsrealit\u00e4t von 114 Patienten mit adulter chronisch nicht-bakterieller Osteitis (CNO) an drei deutschen universit\u00e4ren Zentren \u00fcber den Zeitraum 1985 bis 2025. Prim\u00e4res Ziel war der Abgleich der Therapieverl\u00e4ufe in Deutschland mit den im Jahr 2024 publizierten internationalen Konsensempfehlungen. Die Empfehlungen favorisieren nichtsteroidale Antirheumatika (NSAR) und Coxibe in der ersten und Tumornekrosefaktor-Inhibitoren (TNFi) oder Bisphosphonate in der zweiten Linie der Therapie.<\/jats:p>\n                  <jats:p>Die Ergebnisse zeigen, dass zwar 61\u202f% zuerst NSAR erhielten, aber nur 20\u202f% in der empfohlenen Ausdosierung der Erstlinientherapie. Hingegen erhielten 46\u202f% der adulten CNO-Patienten in der Erstlinie eine konventionell-synthetische Basistherapie (csDMARDs). Diese wird aufgrund der reduzierten Wirksamkeit aktuell nur in Einzelf\u00e4llen empfohlen, wenn eine \u00dcberlappung der adulten CNO mit axialer Spondylarthritis (axSpA) oder Psoriasisarthritis (PsA) vorliegt. Unsere Daten zeigen, dass eine \u00dcberlappung in insgesamt 70\u202f% der adulten CNO-F\u00e4lle auftrat. In der zweiten Linie der Therapie kamen wie empfohlen TNFi zum Einsatz, w\u00e4hrend die alternativ hierzu empfohlenen Bisphosphonate nur bei einem Patienten eingesetzt wurden.<\/jats:p>\n                  <jats:p>Das beobachtete Therapieansprechen betrug, gemessen an der Rate der Therapieabbr\u00fcche, innerhalb von 12\u00a0Monaten maximal 53\u202f%. Die vorliegenden Daten unterstreichen die Relevanz der aktuellen Empfehlungen zur Vereinheitlichung der Terminologie und zur Optimierung der therapeutischen Versorgung von Patienten mit adulter CNO. Ungel\u00f6st bleiben dabei die fehlende ICD-10-Codierung und Zulassung der durch die Konsensempfehlungen vorgeschlagenen Therapie f\u00fcr den deutschen Raum.<\/jats:p>","DOI":"10.1007\/s00393-025-01766-1","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T15:38:53Z","timestamp":1766072333000},"page":"114-125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Behandlung der adulten chronisch nicht-bakteriellen Osteitis in Deutschland","Treatment of adult chronic non-bacterial osteitis in Germany"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2629-1837","authenticated-orcid":false,"given":"Pascal","family":"van Wijnen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7911-4235","authenticated-orcid":false,"given":"Philipp","family":"Klemm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Christofyllakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"M\u00fcller-Ladner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3216-9340","authenticated-orcid":false,"given":"Gunter","family":"Assmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"1766_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003688","author":"SWS Li","year":"2023","unstructured":"Li\u00a0SWS, Roberts\u00a0E, Hedrich\u00a0C (2023) Treatment and monitoring of SAPHO syndrome: a\u00a0systematic review. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2023-003688","journal-title":"RMD Open"},{"key":"1766_CR2","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s00393-021-00979-4","volume":"80","author":"P Klemm","year":"2021","unstructured":"Klemm\u00a0P, Lange\u00a0U (2021) SAPHO syndrome: an overview and nosological differentiation of 35 disease cases. Z\u00a0Rheumatol 80:456\u2013466. https:\/\/doi.org\/10.1007\/s00393-021-00979-4","journal-title":"Z Rheumatol"},{"key":"1766_CR3","first-page":"109","volume":"6","author":"CL Benhamou","year":"1988","unstructured":"Benhamou\u00a0CL, Chamot\u00a0AM, Kahn\u00a0MF (1988) Synovitis-acne-pustulosis hyperostosis-osteomyelitis syndrome (SAPHO). A\u00a0new syndrome among the spondyloarthropathies? Clin Exp Rheumatol 6:109\u2013112","journal-title":"Clin Exp Rheumatol"},{"key":"1766_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/s0950-3579(94)80022-7","author":"M-F Kahn","year":"1994","unstructured":"Kahn\u00a0M\u2011F, Khan\u00a0A (1994) The SAPHO syndrome. Bailliere\u2019s Clin Rheumatol. https:\/\/doi.org\/10.1016\/s0950-3579(94)80022-7","journal-title":"Bailliere\u2019s Clin Rheumatol"},{"key":"1766_CR5","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00296-023-05491-3","volume":"44","author":"T Demirci Yildirim","year":"2023","unstructured":"Demirci Yildirim\u00a0T, Sari \u0130 (2023) SAPHO syndrome: current clinical, diagnostic and treatment approaches. Rheumatol Int 44:2301\u20132313. https:\/\/doi.org\/10.1007\/s00296-023-05491-3","journal-title":"Rheumatol Int"},{"key":"1766_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/ard-2024-226446","volume":"84","author":"E Winter","year":"2025","unstructured":"Winter\u00a0E, Dekkers\u00a0O, Andreasen\u00a0C et\u00a0al (2025) Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults. Ann Rheum Dis 84:169\u2013187. https:\/\/doi.org\/10.1136\/ard-2024-226446","journal-title":"Ann Rheum Dis"},{"key":"1766_CR7","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor\u00a0W, Gladman\u00a0D, Helliwell\u00a0P et\u00a0al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a\u00a0large international study. Arthritis Rheum 54:2665\u20132673. https:\/\/doi.org\/10.1002\/art.21972","journal-title":"Arthritis Rheum"},{"key":"1766_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit\u00a0M, Van Der Heijde\u00a0D, Landew\u00e9\u00a0R et\u00a0al (2009) The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777\u2013783. https:\/\/doi.org\/10.1136\/ard.2009.108233","journal-title":"Ann Rheum Dis"},{"key":"1766_CR9","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.semarthrit.2013.10.010","volume":"43","author":"M Witt","year":"2014","unstructured":"Witt\u00a0M, Meier\u00a0J, Hammitzsch\u00a0A et\u00a0al (2014) Disease burden, disease manifestations and current treatment regimen of the SAPHO syndrome in Germany: results from a\u00a0nationwide patient survey. Semin Arthritis Rheum 43:745\u2013750. https:\/\/doi.org\/10.1016\/j.semarthrit.2013.10.010","journal-title":"Semin Arthritis Rheum"},{"key":"1766_CR10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/rheumatology\/keac443","volume":"62","author":"AT Leerling","year":"2023","unstructured":"Leerling\u00a0AT, Dekkers\u00a0OM, Appelman-Dijkstra\u00a0NM et\u00a0al (2023) Clinical and therapeutic diversity in adult chronic nonbacterial osteomyelitis (CNO) of the sternocostoclavicular region: a\u00a0meta-analysis. Rheumatology 62:512\u2013522","journal-title":"Rheumatology"},{"key":"1766_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10490","author":"AIE Ramautar","year":"2021","unstructured":"Ramautar\u00a0AIE, Appelman-Dijkstra\u00a0NM, Lakerveld\u00a0S et\u00a0al (2021) Chronic nonbacterial osteomyelitis of the sternocostoclavicular region in adults: a\u00a0single-center Dutch cohort study. JBMR Plus. https:\/\/doi.org\/10.1002\/jbm4.10490","journal-title":"JBMR Plus"},{"key":"1766_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.621604","author":"AT Leerling","year":"2021","unstructured":"Leerling\u00a0AT, Ca\u00f1ete\u00a0AN, Ramautar\u00a0AIE et\u00a0al (2021) Sternocostoclavicular hyperostosis: positive clinical and radiological response on pamidronate. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2021.621604","journal-title":"Front Endocrinol"},{"key":"1766_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/ard-2023-224116","volume":"82","author":"M \u00d8stergaard","year":"2023","unstructured":"\u00d8stergaard\u00a0M, van Vollenhoven\u00a0RF, Rudin\u00a0A et\u00a0al (2023) Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial. Ann Rheum Dis 82:1\u201310. https:\/\/doi.org\/10.1136\/ard-2023-224116","journal-title":"Ann Rheum Dis"},{"key":"1766_CR14","series-title":"Scientific Abstracts","first-page":"85","volume-title":"Effectiveness of cobra-slim with or without early access to a temporary 6-month course of etanercept in early Ra: primary outcome of the 2-year, pragmatic, randomised Carera2020 trial","author":"D Bertrand","year":"2023","unstructured":"Bertrand\u00a0D, Joly\u00a0J, Neerinckx\u00a0B et\u00a0al (2023) Effectiveness of cobra-slim with or without early access to a temporary 6\u2011month course of etanercept in early Ra: primary outcome of the 2\u2011year, pragmatic, randomised Carera2020 trial. Scientific Abstracts. BMJ Publishing Group Ltd and European League Against Rheumatism, S\u00a085\u201385"},{"key":"1766_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1136\/annrheumdis-2014-205489","volume":"74","author":"P Verschueren","year":"2015","unstructured":"Verschueren\u00a0P, De Cock\u00a0D, Corluy\u00a0L et\u00a0al (2015) Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16\u00a0weeks of treatment: the CareRA trial. Ann Rheum Dis 74:27\u201334. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205489","journal-title":"Ann Rheum Dis"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01766-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01766-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01766-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:49:26Z","timestamp":1776318566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01766-1"}},"subtitle":["Vergleich zwischen Behandlungsrealit\u00e4t und aktuellen Experten-Konsensempfehlungen","Comparison of real-world practice and current expert consensus recommendations"],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1766"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01766-1","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dieser Artikel wurde urspr\u00fcnglich im Abonnement-Modell ver\u00f6ffentlicht, wird jedoch jetzt unter einer Open-Access-Lizenz ver\u00f6ffentlicht.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"P.\u00a0van Wijnen, P.\u00a0Klemm, U.\u00a0M\u00fcller-Ladner und G.\u00a0Assmann geben an, dass sie Honorare und geldwerte Vorteile durch Teilnahme an Adboards, Forschungsf\u00f6rderung und\/oder Sponsoring zur Kongressteilnahme von AbbVie, UCB, Pfizer, Johnson&Johnson, Novartis und Medac Deutschland im Zeitraum der letzten 5 Jahre erhalten haben. M. Schmidt M und K. Christofyllakis geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt bzw. f\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}